- Price
Supplier Type
- Manufacturer
- Trader
- Reagent
- contract manufacturer
- custom synthesis
Supplier Region
- Hyderabad(7)
- Gujarat(14)
- Maharashtra(14)
- Telangana(1)
- Rajasthan(1)
- Haryana(2)
- Delhi(3)
- Nagpur(2)
- Vadodara(5)
- Mumbai(13)
- Uttar Pradesh(2)
- Tamil Nadu(2)
- Ahmedabad(5)
- Karnataka(4)
- New Delhi(2)
- Andhra Pradesh(2)
- Himachal Pradesh(1)
- Pune(1)
Purity
- VETRANAL?, analytical standard, mixture of isomers
- VETRANAL?, analytical standard
- United States Pharmacopeia (USP) Reference Standard
- Type VI, lyophilized powder
- Type IV-S, lyophilized powder, γ-irradiated, BioReagent, suitable for cell culture
- Type IV-S, lyophilized powder, aseptically processed, BioReagent, suitable for cell culture
- Type IV, lyophilized powder
- tested according to Ph. Eur.
- tech. 10.00%
- suspension, 10,000?unit/mL in DPBS, BioReagent, suitable for cell culture
- suitable for plant cell culture, BioReagent
- suitable for plant cell culture
- suitable for microbiology
- suitable for cell culture
- solid
- Sepharose? conjugate, buffered aqueous suspension
- Selectophore?, function tested, ≥98.0% ((Total homologs), HPLC)
- Ready Made Solution, from Streptomyces alboniger, 10?mg/mL in H2O, suitable for cell culture
- Ready Made Solution, 100?mg/mL in ethanol/water, 0.2 μm filtered
- Ready Made Solution, 10?mg/mL in DMSO
- powder, γ-irradiated, BioXtra, suitable for cell culture
- powder, BioXtra, suitable for mouse embryo cell culture
- powder, BioReagent, suitable for cell culture, suitable for plant cell culture
- powder, BioReagent, suitable for cell culture
- powder, ≥98% (TLC)
- powder
- phyproof? Reference Substance
- Pharmaceutical Secondary Standard
- peroxidase conjugate, lyophilized powder
- penicillin analog
- mixture of Kanamycin A (main component) and Kanamycin B and C
- Min. 99%
- meets USP testing specifications, powder
- lyophilized powder, recombinant, expressed in E. coli
- lyophilized powder, BioReagent, suitable for cell culture
- lincosamide antibiotic
- InSolution, ≥99%
- InSolution, ≥97%, 1 mM solution, protein kinase inhibitor
- InSolution, ≥95%, 25 mM in DMSO
- IgG fraction of antiserum, buffered aqueous solution
- HCl dihydrate 95%
- Greater than 99%
- from Streptomyces parvulus, ≥98% (HPLC)
- from Streptomyces luteosporeus, ≥95% (HPLC)
- from Streptomyces chattanoogensis, ≥95% (HPLC)
- from Sorangium cellulosum, ≥98% (HPLC)
- from Penicillium brefeldianum, Ready Made Solution, 10?mg/mL in DMSO
- from Penicillium brefeldianum, ≥99% (HPLC and TLC)
- for synthesis
- for molecular biology, ≥95% (HPLC)
- FITC conjugate, Type IV, lyophilized powder
- European Pharmacopoeia (EP) Reference Standard
- Endotoxin (BET) 10EU/mg
- Endotoxin (BET) 0.05EU/mg
- Dye content 95?%
- Dye content ≥55?%
- clone 893CT29.1.1, IgG fraction of antiserum, buffered aqueous solution
- certified reference material, pharmaceutical secondary standard
- Certified Reference Material
- Cell-permeable fungal toxin.
- Cefaperazone Sodium)
- British Pharmacopoeia (BP) Reference Standard
- biotin conjugate, Type IV, lyophilized powder
- BioReagent, suitable for fluorescence, ≥98.0% (NT)
- Antiprotozoal agent and angiogenesis inhibitor.
- antibacterial MurA inhibitor
- Animal Component-free
- anhydrous basis)
- and E (7%) isomers 99% (HPLC)
- analytical standard
- An antifungal antibiotic that inhibits sterol and fatty acid biosynthesis.
- agarose conjugate, Type VI, saline suspension
- A polyene antifungal antibiotic effective against yeast and mycoplasma.
- 99.99999%
- 99.0%
- ≥99% (HPLC)
- ≥99% (HPLC and TLC), BioXtra, for molecular biology
- 99%
- >99%
- 99 %
- 98-102%
- 98.82%
- >98.0%(T)(HPLC)
- >98.0%(T)
- >98.0%(N)
- >98.0%(HPLC)(N)
- >98.0%(HPLC)
- 98%min
- ≥98%, synthetic
- ≥98% Z isomer
- 98% Min
- ≥98% (TLC)
- ≥98% (HPLC), solid
- >98% (HPLC), powder
- ≥98% (HPLC), powder
- ≥98% (HPLC), from Cephalosporium caerulens
- ≥98% (HPLC), film
- ≥98% (HPLC)
- 98%
- >98%
- >97.0%(N)
- >97.0%(HPLC)(N)
- ≥97% (HPLC)
- 97%
- 97 %
- 96.12%
- >96.0%(GC)
- 96%
- 95-103%
- 95.0-102.0% anhydrous basis
- >95.0%(T)(N)
- >95.0%(T)(HPLC)
- >95.0%(N)
- >95.0%(HPLC)(qNMR)
- >95.0%(HPLC)
- ≥95% (HPLC), powder
- ≥95% (HPLC)
- ≥95% (HPLC and TLC)
- 95%
- >94.0%(N)
- 920
- >92.0%(HPLC)
- ≥92% (HPLC), powder
- >90.0%(N)
- >90.0%(HPLC)
- ≥90.0% (Cephradine, HPLC)
- ≥90%, powder
- ≥90% (HPLC)
- 90%
- 90 % Above
- 870 - 1015 μg/mg anhydrous basis
- 86-100%
- 860u/mg
- 85011426
- ≥85% (HPLC)
- 815-950?μg/mg (Oxacillin)
- 8?mg/mL in 0.9% NaCl, 0.1 μm filtered, BioReagent, suitable for cell culture
- 795ug/mg
- 750mcg/mg
- ≥75% α-anomer basis, ≥98% (HPLC), powder
- 720 IU/mg
- ≥70% (UV)
- ≥634ug/mg
- ≥630ug/mg
- >600IU/mg
- 590ug/mg
- 50 - 60?mg/mL in 0.9% NaCl, BioReagent, liquid, 0.1 μm filtered, suitable for cell culture
- ≥4,400?USP units/mg
- 1300u/mg
- 100%
- 10?mg/mL in H2O, ≥98% (HPLC), Cell culture tested
- 10?mg/mL in DMSO
- 10?mg/mL in 0.9% NaCl, 0.1 μm filtered, BioReagent, suitable for cell culture
- 10%
- ~50?μg/mL in acetonitrile, analytical standard
- ~2.5% (γ-irradiated Pimaricin), aqueous suspension
- ~1?mg/mL in 1 mM EDTA, analytical standard
- (BET) 0.05EU/mg
Package
- 0.1mg
- 100μg
- 200μg
- 250μg
- 0.5mg
- 500μg
- 1mg
- 2mg
- 5mg
- 10mg
- 15mg
- 20mg
- 25mg
- 40mg
- 50mg
- 60mg
- 70mg
- 75mg
- 80mg
- 100mg
- 110mg
- 120mg
- 125mg
- 150mg
- 160mg
- 170mg
- 180mg
- 200mg
- 250mg
- 260mg
- 300mg
- 350mg
- 400mg
- 0.5mL
- 500mg
- 700mg
- 1g
- 1mL
- 1gm
- 2mL
- 2g
- 5gm
- 5g
- 10x1mL
- 10mL
- 20mL
- 25g
- SAMPLE-K
- 5mL
- 10g
- 10gm
- 25mL
- 25gm
- 1VIAL
- 50g
- 50mL
- 2ea
- 100mL
- 100g
- 100gm
- 250G
- 500gm
- 500g
- 1kg
- 5kg
- 10kg
- 25kg
- 1 Gms
- 1MT
- 5vials
- 11Between 1 gm to 1 MT (As per availability)
- 1and gm
- 1Gms
- 5Gms
- 5units
- 0.18
- 2Gms
- 10Gms
- 18%
- 200μL
- 400μL
- 500000units
- 5000000units
- 25000000units
- 85011426-DNA-5UG
- 25Gms
- 100 Mg
- 100Gms
(2-Amino-4-thiazoyl) Acetic acid 29676-71-9
2-(2-aminothiazol-4-yl) acetic acid 29676-71-9
2-(2-Aminothiazol-4-yl) acetic acid 29676-71-9
Oseltamivir phosphate 204255-11-8










